- Dr. R. Martin Chavez is joining the board of directors at Paige, a leader in computational pathology transforming the diagnosis and treatment of cancer
Paige — a leader in computational pathology transforming the diagnosis and treatment of cancer — announced it has welcomed Dr. R. Martin Chavez to its board of directors. Chavez is joining the Paige board of directors after he retired from Goldman Sachs where he worked in multiple roles over 19 years, including as CIO, CFO, and Co-Head of Securities.
Chavez has been credited as one of the key figures in elevating the roles of engineering and data science at Goldman Sachs and broadly in the financial services sector. And at Paige, Chavez plans to drive similar transformations in healthcare.
Paige recently closed $45 million in a Series B round of funding. And Chavez will be instrumental in working with executives as they grow the product portfolio at the company and expand into biopharma services.
“I’m thrilled at the opportunity to put my experience at the crossroads of math, data, software, and machine learning to work for the crucial mission of revolutionizing cancer prognosis and treatment,” said Chavez (who holds a Ph.D. in Medical Information Sciences from Stanford University). “I’m looking forward to joining Paige’s team in driving forward computational models for human tissue while building a world-class culture of engineering, data science, and clinical decision analysis.”
Before joining Goldman Sachs, Chavez was CEO and co-founder of Kiodex (acquired by Sungard in 2004). And he was also CTO and co-founder of Quorum Software Systems. Plus he currently serves on the Board of Overseers of Harvard University, the Stanford Medicine Board of Fellows and the Board of Trustees of the Institute for Advanced Study.
“I couldn’t be more excited to welcome Marty to our active and influential board of directors,” added Leo Grady, CEO at Paige.AI. “He has been enormously successful as an entrepreneur and leader. At Paige, we intend to transform cancer care in the same way that Marty transformed finance, which will have a far-reaching impact on clinical medicine and drug development. Marty will be very hands-on with us, along with Jim Breyer and our other board members, to build a truly transformative healthcare company.”
Chavez is joining the Paige board of directors following a big year of significant momentum for Paige. Grady joined Paige in February 2019 and the company went on to receive the first FDA breakthrough designation in the same month. And the company ended the year by receiving the first CE mark for a computational pathology solution called Paige Prostate.
